

Clearbridge appoints renowned oncologist to Medical Advisory Board

Professor Soo Khee Chee is known for his work in conducting clinical trials for new cancer treatments, and in the field of biophotonics.

SINGAPORE – 27 August 2018 – Clearbridge Health Limited (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (明策集团), a healthcare company with a focus on the delivery of precision medicine in Asia, has appointed renowned oncologist, Professor Soo Khee Chee, to its Medical Advisory Board.

As a medical specialist for more than 40 years - 30 of which were in Singapore’s public healthcare system - Professor Soo’s most notable achievements include establishing the National Cancer Centre Singapore (“NCCS”) as a leading cancer institution, recognised globally for its research in lymphoma, head and neck, nasopharyngeal, liver and lung cancers, during his tenure as its founding Director.

Professor Soo, driven by his passion to nurture, has trained young doctors and international surgeons alike. He has served as Senior Vice Dean of Clinical, Academic and Faculty Affairs at Duke-NUS Graduate Medical School Singapore and was a Visiting Professor at the University of Toronto (Canada), Jaslok Hospital and Research Centre (Mumbai, India), and Stanford University Medical Center (USA). He is also a Professor of Surgery at the National University of Singapore, and was instrumental in SingHealth’s partnership with North Carolina’s Duke University which brought Duke-NUS Medical School to the Singapore General Hospital Campus.

For his contribution towards training and education, Professor Soo was bestowed the Outstanding Teachers’ Award and Best Teacher (Undergraduate) Award in 1996 and 2001 respectively. In 2003, he was awarded the Public Administration Medal (Gold) in recognition of his outstanding efficiency, competence and industry. He was also awarded the National Outstanding Clinician Mentor Award in 2008 for his contribution to the healthcare industry, specifically in the training of young clinicians and setting up a conducive clinical and research environment. In 2011, Professor Soo was conferred the Benjamin Sheares Professorship Award for his pioneering contributions to research, scholarship, and clinical service in the practice of medicine in Singapore. In the same year, Professor Soo was also conferred with the President’s Science & Technology Award (PSTA).

In the field of research, Professor Soo has gained a reputation particularly in the conduct of clinical trials for new cancer treatments, in the field of biophotonics and its role as a new imaging modality for the early detection of cancer.

In December 2017, Professor Soo moved into the private sector and started his own surgical practice in Farrer Park Hospital and Farrer Park Medical Centre with an interest in surgical oncology and head and neck surgery. He still continues to contribute to the public sector as a senior visiting consultant at



NCCS and SingHealth, and remains a lead principal investigator in the Tan Chin Tuan Laboratory of Optical Imaging and Photodynamic Therapy of Cancer at NCCS.

Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, said: *“Clearbridge is honoured that someone of Professor Soo’s credentials has agreed to serve on our Medical Advisory Board. With our focus on precision medicine, we share Professor Soo’s keen interest in cancer medical research and leveraging technology to achieve better detection and treatment outcomes for patients. We look forward to tapping on his extensive experience to advise the Group and guide us in our goal of researching diagnostic and treatment techniques for Asian genetics and providing ever more effective ways to detect cancer, critical illness, and other lifestyle diseases.”*

###

About Clearbridge Health Limited

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients. For more information, please visit us at www.clearbridgehealth.com.

Issued by and on behalf of Clearbridge Health Limited

August Consulting

Tel: +65 6733 8873

Silvia Heng, silviaheng@august.com.sg

Wrisney Tan, wrisneytan@august.com.sg

Zavier Ong, zavierong@august.com.sg

This press release has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, United Overseas Bank Limited (the “Sponsor”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the “SGX-ST”).

The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.